“Phase 3 Trial Demonstrates Superior Patient Treatment Convenience of MC2-01 Calcipotriene Plus Betamethasone Dipropionate Cream Compared to Current Topical Suspension”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s62, https://doi.org/10.25251/skin.4.supp.61.